McKesson Stock May Rise With PRISM Vision Holdings Acquisition

McKesson Corporation MCK recently announced that it has signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a premier provider of general ophthalmology and retina management services, from Quad-C.McKesson is likely to purchase an 80% stake in  PRISM Vision Holdings for approximately $850 million, while physicians will continue to retain a 20% interest.Likely Trend of MCK Stock Following the NewsFollowing the announcement, shares of the company closed flat at $603.3 on Tuesday. In the past six months, MCK shares have lost 1.7% against the industry’s 5.7% growth. The S&P 500 increased 15.6% in the same time frame.The acquisition of a controlling stake in PRISM Vision Holdings positions McKesson as a leader in the growing specialty eye care market. This strategic move enhances its portfolio in ophthalmology, diversifies revenue streams, and strengthens its long-term specialty care infrastructure. By addressing increasing demand in a niche healthcare segment, McKesson demonstrates a commitment to growth and innovation, which can improve investor confidence and drive stock performance over time.Meanwhile, MCK currently has a market capitalization of $76.14 billion. In the last reported quarter, MCK delivered an earnings surprise of 2.61%.Image Source: Zacks Investment ResearchMore on MCK’s Acquisition of PRISM VisionThe acquisition of PRISM Vision Holdings allows McKesson to strengthen its leadership in community-based specialty care, particularly in the high-growth field of retina and ophthalmology. By leveraging PRISM Vision Holdings' expertise in retinal care and clinical research, McKesson can create a comprehensive platform for providers, biopharma partners, and patients. This move builds on McKesson's proven oncology solutions, enhancing its ability to deliver innovative care while addressing unmet needs in ophthalmology.This acquisition supports McKesson's strategy to establish a leading retinal and ophthalmology platform, enhancing its clinical services, distribution offerings, and value proposition. PRISM Vision Holdings' network of over 180 providers, 91 office locations, and seven ambulatory surgery centers should help McKesson expand its data and analytics capabilities, drive innovation in clinical research, and deepen partnerships with biopharma companies.Once the transaction is completed, PRISM Vision Holdings is likely to be integrated into McKesson's U.S. Pharmaceutical segment. The deal is subject to standard closing conditions, including regulatory approvals. Following the closure, PRISM Vision is expected to contribute an estimated $0.20 to $0.30 to McKesson’s adjusted earnings per diluted share in the first 12 months and increase to $0.65 to $0.75 by the end of the third year following the close of the transaction.MCK’s Notable Recent DevelopmentsIn December 2024, MCK announced the completion of its divestiture of Canada-based Rexall and Well.ca businesses. The divestiture is expected to enable McKesson to focus on capital deployment and prioritize investments in expanding its strategic oncology and biopharma growth platforms.In November 2024, MCK exited the second quarter of fiscal 2025 on a strong note, with earnings and revenues improving year over year. Revenues reflected strong momentum in the U.S. pharmaceutical segment, driven by robust demand across its offerings. The company added a large distribution customer to its portfolio during the fiscal first quarter, which strongly benefited the segment in the second quarter.MCK’s Zacks Rank & Stocks to ConsiderMCK carries a Zacks Rank #3 (Hold) at present.Some better-ranked stocks in the broader medical space are Masimo MASI, ResMed Inc. RMD and Cardinal Health CAH.Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 11.8% for 2025. MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 51.4% compared with the industry’s 6.8% growth in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.ResMed, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 14.8%. RMD’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.4%.ResMed has gained 32.4% compared with the industry’s 16.5% growth in the past year.Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.5%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%.Cardinal Health’s shares have gained 21.7% compared with the industry’s 6.1% growth in the past year.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks